Comparable: structured measurement intended for within-endpoint comparison when assay context matches
Assay / model
EU Clinical Trials Register PKD11475 results manual extraction · human · plasma
Condition
Route: subcutaneous · Dose/window: single 10 mcg lixisenatide; paediatric patients with type 2 diabetes; N=8; sampling through 6.5 hours post-dose · Time: day 1
